Close Menu
March 23, 2020
Sponsored by
LGC

Rapid Response to the Coronavirus Outbreak: How Collaboration Meets the Challenge

GenomeWebinar

In this webinar, Joseph Featherstone and Dr. Brent Satterfield from Co-Diagnostics (CoDx) will present insights into the development of the CoPrimer COVID-19 test. They will discuss how innovative design algorithms and a close partnership with a critical component supplier, LGC, Biosearch Technologies, enabled assay design and verification in seven days, making the COVID-19 test available for market. Brent will provide details of the CoPrimer technology and how the new algorithm enabled rapid assay design, while Joseph will share the latest developments toward clinical validation of the assay as well as discuss the CoDx Portable qPCR Lab and its impact in the field.

Dr. Geert Koene from Biosearch Technologies will share the perspective of a component supplier and will discuss details of the company's proprietary BHQ technology, experience in reacting to outbreaks, and the importance of a collaborative partnership.

Sponsored by

The US has sent its formal notice of withdrawal from the World Health Organization, according to the Wall Street Journal.

Science reports that a draft spending bill would increase the US National Institutes of Health budget by 13 percent.

The Harvard Crimson reports that Harvard and MIT are suing the Department of Homeland Security and ICE over the new international student visa policy.

In Nucleic Acids Research this week: algorithm to determine molecular sequence types and other microbial features, computational method to uncover R-loop structures, and more.

Jul
15
Sponsored by
LGC SeraCare Life Sciences

Cancer immunotherapy is an exciting new advance for the successful treatment of many forms of metastatic cancer.

Jul
16
Sponsored by
NanoString

Join this webinar to learn how spatial resolution of gene expression in tumor tissue reveals new insights in biomarker discovery and therapeutic response. 

Jul
23
Sponsored by
Roche

This webinar will discuss a study that set to assess the efficacy and safety of osimertinib in EGFR T790M positive non-small cell lung cancer (NSCLC) patients identified by using plasma sample and cobas EGFR Mutation test v2. This is the first prospective study to use liquid biopsy upfront to evaluate osimertinib efficacy.

Aug
25
Sponsored by
Roche

Non-small cell lung cancer (NSCLC) patients with ALK rearrangements are treated with tyrosine kinase inhibitors (TKIs), which often leads to prolonged overall survival. However, treatment resistance will almost inevitably occur, and the disease remains incurable.